We demonstrate that treatment with two well-characterized small-molecule inhibitors of HMGB1, EP and GA,70–72 prevents intraneuronal HMGB1 translocation and release and leads to a striking reduction in a variety of prominent AD pathologies in APOE4-tauopathy mice. Here, HMGB1 is linked to tauopathy.